tradingview.com
Cure8 news brief
Eli Lilly's Omvoh boosted by new ulcerative colitis, Crohn's data - TradingView
Medications
Mirikizumab
IL-23 inhibitor
Biomarkers
Biomarker
Remission
Phase 3 clinical trial
Adult patients
Why This Matters
Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed biologics—findings that could affect treatment choices if confirmed and approved.
Who Should Pay Attention
Adults with moderate-to-severe ulcerative colitis or Crohn’s disease, especially those who have failed prior biologic therapies; clinicians treating IBD; researchers following new biologic therapies.
Study Snapshot
Story typeBusiness news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
The article summarizes results from two phase 3 trials.
In LUCENT-2 (ulcerative colitis), a composite outcome called “comprehensive disease control” at one year — combining symptomatic, endoscopic, histologic remission, biomarker normalization, and no corticosteroid use — was reported for a larger share of patients on Omvoh versus placebo, including a benefit in patients with prior biologic failure.
In VIVID-1 (Crohn’s disease), a one-year corticosteroid-free deep remission outcome also favored Omvoh vs placebo, with benefit noted among patients who had failed prior biologic treatment.
These are trial outcome summaries reported by a financial news aggregation (Seeking Alpha/TradingView); the article does not provide full study publications, detailed safety data, or regulatory context. Discuss treatment options and safety with your clinician before making any decisions.
Keep In Mind
The article is a news-summary based on Seeking Alpha content; it reports selected trial endpoints and percentages but does not link to full peer-reviewed publications or provide comprehensive safety and regulatory details. Phase 3 trial outcomes are promising but should be interpreted alongside full study reports and guidance from clinicians.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationtradingview.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 15, 2026, 3:44 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and ...
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
Most patients on Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease achieved sustained clinical remission and endoscopic response at two years
This press release reports multi-year clinical trial data suggesting sustained remission and intestinal healing with Omvoh (mirikizumab) in patients with Crohn's disease—information that could affect treatment...
Eli Lilly Reports Positive One-Year Omvoh Data In Ulcerative Colitis, Crohn's Disease
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.